VistaGen’s stem cell technology is directed at once-promising drug candidates that had to be discontinued during development due to heart toxicity issues. Traditional toxicity testing of new drug candidates takes place in animal studies and human clinical trials during the final stages of development. Such testing suffers from a significant lack of accuracy in predicting future toxicity, and occurs well after significant resources have been invested to bring the drug along. The result too often represents a major financial loss to the developer, when toxicity problems are discovered. In addition, if the drug has already gone to market, the lives of patients can be jeopardized.
Through the use of VistaGen’s Human Clinical Trials in a Test Tube approach, stem-cell derived functional human heart cells can be used in highly accurate laboratory testing of new drug candidates, before the investment in further development or clinical trials. Such early-stage testing saves money and time, allowing the developer to make adjustments when and if problems are found. Moreover, previously withdrawn drug candidates can potentially be rescued through this efficient and cost-effective test tube approach, turning a major financial loss into a revenue-generating asset.
For additional information, visit the company’s website at www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
